Live
Funding 2 min read

Denmark’s Commit Biologics secures €54 million Seed funding to advance cancer and autoimmune therapies

Copenhagen-based biotech startup Commit Biologics has raised €54 million ($60 million) in Seed funding to develop treatments for cancer and autoimmune diseases. The funding will enable the company to advance its first drug candidate towards clinical trials.

Image: EU-Startups Denmark

Commit Biologics, a Copenhagen-based biotech startup, announced that it has raised €54 million ($60 million) in Seed funding aimed at advancing treatments for cancer and autoimmune diseases. This substantial investment will enable the company to bring its initial drug candidate closer to clinical trials, marking a significant step in its development.

The funding round was led by Ackermans & van Haaren, with additional contributions from new investors AbbVie Ventures and M Ventures, along with existing backers Bioqube Ventures, Korys, and Novo Holdings. CEO Dr. Thomas L. F. Montgomery Andresen emphasized the pride in having strong financial support, indicating the importance this financing holds for their future in immunotherapy.

With this financing secured, Commit Biologics plans to advance their drug candidate COM002 into clinical trials, establishing a foundation for further developments in complement-powered immunotherapy.

Reporting sources

Where this story comes from

1 reference

The facts above are grounded in the original reporting linked here. Open the publisher story for its complete context.

EU-Startups Denmark Open source

Denmark’s Commit Biologics secures €54 million Seed funding to advance cancer and autoimmune therapies

The available publisher preview does not add detail beyond this brief. Open the original report for its full context.

Related coverage

Story history

This article is awaiting history analysis.

About this history review

The link graph’s cryptographic signature was verified. This proves integrity, not the truth of every claim or complete archive coverage.

Graph updated . Only articles retained in the public archive are included.

Open technical link data
Method & transparencyHow this brief was selected and checked
Editorial priority5 / 10

Tracked

Source coverageSingle-source report

Single-source report

ConfidenceLimited

44 / 100 · one source

Source basis

Grounded in the publisher material listed below.

Confirmation

No second independent source has been matched to this story yet.

Selection

Selected for publication after relevance, freshness and editorial-quality checks.

Selection factors

  • 1 independent source
  • 1 concrete event indicator
  • fresh coverage
  • editorial priority
  • noise score 4/10

Source monitoring: 100% recent availability · No source-health warnings. The original publisher remains the authoritative source for the full report.